Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
6 Results Found
Urge Your Representative to Sign Letter for HHS to Act on J&J 340B Proposal
Reps. Abigail Spanberger (D-Va.), Dusty Johnson (R-S.D.), Doris Matsui (D-Calif.), Debbie Dingell (D-Mich.), Tracey Mann (R-Kan.) and Rob Wittman (R-Va.) are asking representatives to sign onto a letter to the Department of Health and Human Services urging it to take action to stop Johnson & Johnson’s (J&J) plan “to upend more than 30 years of federal law by delaying access to 340B Drug Pricing Program (340B) discounts on pharmaceuticals for certain safety-net hospitals.”
AHA Comments on 340B Drug Pricing Program, IRF Payments, Physician Fee Schedule and Telehealth
AHA comments on MedPAC topics to be considered in the new cycle: the 340B Drug Pricing Program, inpatient rehabilitation facility (IRF) payments, the physician fee schedule (PFS) and telehealth.
AHA 340B Advocacy Alliance Bulletin - March 20, 2023
Deceptively branded as an effort to save the 340B program, a legislative campaign by the Pharmaceutical Research and Manufacturers of America, National Association of Community Health Centers and other groups to remove many hospitals, eligible drugs and patients from the 340B program “would only save drug company profits by reducing their already modest financial contribution to the health care safety net,” the AHA and other national hospital groups said in a statement today.
AHA 340B Advocacy Alliance Bulletin - July 22, 2022
The Centers for Medicare & Medicaid Services July 15 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system rates by a net 2.7% in calendar year 2023 compared to 2022.
340B Advocacy Alliance Bulletin: Updates on 340B Legislation, Representatives Letter to HHS
Updates on 340B Legislation, Representatives Letter to HHS
Deadline Extended Until Oct. 29 for Your Representatives to Sign ‘Dear Colleague’ Letter Urging HHS to Take Action
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary Alex Azar expressing concern about recent efforts by Kalderos to transition the 340B Drug Pricing Program from one of up-front discounts to post-sale rebates.